The regulator approved two interchangeable biosimilars to Regeneron’s Eylea, providing additional competition for the pharma’s blockbuster as key patent protections are set to expire.
“We want to introduce Precision AQ as a team of advisors, experts, and creators to sit in the room with our clients to partner, looking at access as a continuum,” President Doug Fulling told Med Ad News. “This has been 10 years in the making. We started the rebrand process six months ago, but the reason that we’re doing this now is we want to simplify our North Star and where we’re going in the marketplace.”
The Boston-based drug developer will use its proprietary technology along with Lilly’s expertise in oncology drugs to develop therapies for a range of solid tumors.
Today the company announced that its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
The drug, called depemokimab, showed “significant and meaningful reductions” in asthma attacks for patients with eosinophilic asthma, the company stated.
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries.